{
  "abstract": "We gathered to discuss the DexEnceph trial, a phase 3 randomised controlled trial (RCT) evaluating adjunctive intravenous dexamethasone (10 mg four times per day for 4 days) in adults with herpes simplex virus encephalitis (HSE), confirmed by PCR and receiving standard-of-care aciclovir.1 Given the substantial morbidity of HSE and the longstanding uncertainty around corticosteroids,2 we felt this study could potentially inform clinical practice.",
  "authors": [
    {
      "affiliations": [
        "Department of Neurology, Charing Cross Hospital, London, Greater London, UK"
      ],
      "name": "Emer O’Connor"
    },
    {
      "affiliations": [
        "Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada"
      ],
      "name": "James E Burns"
    },
    {
      "affiliations": [
        "Lancaster University Faculty of Health and Medicine, Lancaster, UK",
        "Royal Preston Hospital, Preston, UK"
      ],
      "name": "Laura M White"
    },
    {
      "affiliations": [
        "Nuffield Department of Clinical Neurosciences, Oxford University Hospitals NHS Foundation Trust, Oxford, England, UK",
        "Dept of Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"
      ],
      "name": "Sophie N M Binks"
    }
  ],
  "title": "Journal club: safety and efficacy of adjunct dexamethasone in adults with herpes simplex virus encephalitis in the UK (DexEnceph)—a multicentre, observer-blind, randomised, phase 3, controlled trial",
  "uid": "cf70c642-a0b1-5d6f-b791-4d37abf69795"
}